96 completed, 22 active not recruiting, 21 unknown, 20 terminated. 183 Phase 3, 9 Phase 2.
By phase and status
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Trials (filtered) newest first · largest first
All 183 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | 63 | 2026-09-15 | 2026-10-14 |
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 620 | 2026-08-03 | 2026-08-31 |
A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
TQB3909 Tablets, Bendamustine Injection, Rituximab injection - Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 3 | Not yet recruiting | 128 | 2026-08-01 | 2026-08-11 |
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Gamunex-C, 10% Injectable Solution - Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Phase 3 | Recruiting | 49 | 2026-05-11 | 2026-10-01 |
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Surovatamig - Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV | Phase 3 | Recruiting | 420 | 2026-05-05 | 2026-10-06 |
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Zanubrutinib, Sonrotoclax, Computed Tomography - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 3 | Recruiting | 466 | 2026-04-30 | 2026-10-02 |
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 3 | Recruiting | 306 | 2026-04-23 | 2026-08-11 |
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Sonrotoclax, Zanubrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 500 | 2026-01-22 | 2026-09-28 |
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
DZD8586, Bendamustine, Idelalisib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 250 | 2025-09-08 | 2026-06-03 |
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Tacabrutideg, Pirtobrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 500 | 2025-09-04 | 2026-09-28 |
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
Venetoclax, Azacitidine - Leukemia, B-Cell, Chronic, Leukemia | Phase 3 | Not yet recruiting | 262 | 2025-09-01 | 2025-07-24 |
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Sonrotoclax, Obinutuzumab, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 630 | 2025-06-11 | 2026-10-23 |
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
BGB-16673, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 153 | 2025-05-29 | 2026-08-24 |
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 250 | 2025-04-10 | 2026-09-28 |
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Venetoclax, Acalabrutinib, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 170 | 2024-08-05 | 2026-04-09 |
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
American Ginseng, Placebo Administration, Questionnaire Administration - Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 222 | 2024-08-01 | 2026-10-20 |
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Liso-cel, Idelalisib, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Withdrawn | | 2024-01-16 | 2024-04-02 |
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Nemtabrutinib, Ibrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 1200 | 2023-12-13 | 2026-10-13 |
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Sonrotoclax, Zanubrutinib, Venetoclax - CLL | Phase 3 | Active not recruiting | 652 | 2023-11-11 | 2026-10-14 |
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Nemtabrutinib, Venetoclax, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic | Phase 3 | Recruiting | 735 | 2023-08-08 | 2026-10-15 |
Showing 20 of 183. Sign in to see all of them.
Narrower conditions
Leukemia, Lymphocytic, Chronic, B-Cell (176) · Lymphoma, Non-Hodgkin (55) · Lymphoma, Follicular (54) · Lymphoma, B-Cell, Marginal Zone (47) · Lymphoma, Mantle-Cell (45) · Lymphoma, Large B-Cell, Diffuse (42) · Lymphoma (41) · Leukemia (39) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (39) · Multiple Myeloma (37) · Burkitt Lymphoma (36) · Lymphoma, Large-Cell, Immunoblastic (36) · Hodgkin Disease (35) · Leukemia, Myeloid, Acute (29) · Leukemia, Myeloid, Chronic-Phase (26)
Broader conditions
Hemic and Lymphatic Diseases (183) · Immune System Diseases (183) · Immunoproliferative Disorders (183) · Lymphatic Diseases (183) · Neoplasms by Histologic Type (183) · Leukemia, Lymphoid (182) · Hematologic Diseases (179) · Lymphoproliferative Disorders (177) · Chronic Disease (176) · Disease Attributes (176) · Pathologic Processes (176) · Pathological Conditions, Signs and Symptoms (176) · Neoplasms (165) · Leukemia (144)
Interventions
Rituximab (50) · Cyclophosphamide (29) · Bendamustine Hydrochloride (28) · venetoclax (26) · obinutuzumab (24) · ibrutinib (23) · Chlorambucil (22) · fludarabine (18) · fludarabine phosphate (16) · idelalisib (13) · acalabrutinib (11) · ofatumumab (9) · pirtobrutinib (7) · Cyclosporine (5) · Mycophenolic Acid (5)
Sponsors
German CLL Study Group (12) · Gilead Sciences (10) · Hoffmann-La Roche (10) · BeOne Medicines (6) · Fred Hutchinson Cancer Center (6) · National Cancer Institute (NCI) (6) · AbbVie (5) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Acerta Pharma BV (4) · Alliance for Clinical Trials in Oncology (4) · AstraZeneca (4) · Janssen Research & Development, LLC (4) · Loxo Oncology, Inc. (4) · Merck Sharp & Dohme LLC (4) · Novartis Pharmaceuticals (4)
Countries
United States (122) · United Kingdom (63) · France (62) · Italy (60) · Germany (59) · Spain (57) · Australia (53) · Canada (53) · Poland (51) · Belgium (45) · Czechia (40) · Sweden (37) · Austria (35) · Israel (35) · Russia (34)
Top investigators
Michael Hallek, MD (7) · Barbara Eichhorst, MD (2) · Barbara Eichhorst, MD, Prof. (2) · Brenda Sandmaier (2) · David J. Straus, MD (2) · Hagop Youssoufian, MD (2)
Results publications
PMID 38620092, PMID 40266025, PMID 28751558, PMID 31196847, PMID 33131249, PMID 34865212, PMID 24797299, PMID 24916506, PMID 25103870, PMID 29255066, PMID 29880603, PMID 32499241, PMID 32599655, PMID 32735048, PMID 35014928, PMID 35377947, PMID 35829925, PMID 36617990, PMID 38502198, PMID 38598745, PMID 39563886, PMID 40396505, PMID 40944848, PMID 41749915, PMID 15459300, PMID 16148284, PMID 16219797, PMID 16344317, PMID 16710026, PMID 17283363, PMID 17283364, PMID 17296974, PMID 17389338, PMID 17397698, PMID 17658394, PMID 17889355, PMID 18293016, PMID 19016733, PMID 19270260, PMID 19605849, PMID 19738118, PMID 20511662, PMID 20888994, PMID 21139079, PMID 21483000, PMID 21659360, PMID 21992852, PMID 22157574, PMID 22168274, PMID 22337714
NIH funding
2023 (7), 2009 (4), 2015 (4), 2025 (4), 2014 (3), 2019 (3), U10CA021115 (3), 2005 (2), 2008 (2), 2017 (2), 2018 (2), P01CA015396 (2), P30CA006973 (2), P30CA015704 (2), P30CA036727 (2)